Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ritonavir, saquinavir combination--& warning.

AIDS treatment news - 29 Sept 1995

Abstract excerpt

The combination of Abbott's ritonavir and Roche's saquinavir, two protease inhibitors, must be used with caution. The saquinavir dose must be drastically reduced, but by how much is not yet known. It is hoped that by using the combination, HIV drug resistance will be delayed. Ritonavir's ability to block a liver enzyme responsible for metabolizing and eliminating saquinavir, thus increasing its concentration in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Half-Life
Share to Inactivation, Metabolic
Share to Isoquinolines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Quinolines

Share to Ritonavir

Share to Saquinavir

Share to Thiazoles

Share to Valine

Source

Identifiers

PMID: 11362871

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ritonavir, saquinavir combination--& warning.PMID 11362871Read ↗

Protease inhibitors: drug resistance and cross resistance overview.Semantic proximity Read ↗

Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.Semantic proximity Read ↗

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study.Semantic proximity Read ↗

Rational approaches to resistance: using saquinavir.Semantic proximity Read ↗

Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.Semantic proximity Read ↗

Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.Semantic proximity Read ↗

Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.Semantic proximity Read ↗

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.Semantic proximity Read ↗

Conference highlight.Semantic proximity Read ↗

Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.Semantic proximity Read ↗

Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.Semantic proximity Read ↗

Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.